News - Pharmaceuticals
Robust ethics and compliance programs facilitate strong economic performance in APEC region

Pharma News: In the face of the disruptions to the global supply chain due to the COVID-19 pandemic, companies across the APEC region scrambled to adjust operations while enabling the continued flow of goods and services.
Small and medium-sized enterprises (SMEs) in healthcare with high or medium ethics program maturity had stronger economic performance during the COVID pandemic, according to new research.
The study breaks new ground in measuring the positive return of ethics on the bottom line. It was done in collaboration with Professor Laura Spence of the University of London Royal Holloway and made possible through co-funding by the Asia-Pacific Economic Cooperation forum (APEC) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), in the context of APEC’s new Vision 2025 roadmap.
More than two-fifths (43%) of companies surveyed reported having increased their investment in ethics and compliance resources during the pandemic, and only 6% reduced their investment. Among those who increased investment, the most common reasons cited were increased focus on compliance from the industry (52.8%), an increased focus on compliance from society (39.9%), and specific requests from domestic and international customers/partners (each at 33.7%).
Sophie Hibburd, Head of Ethics and Compliance at Medicines Australia told Health Industry Hub “This report underscores the importance of having strong compliance programs. Our partners are looking at not only what we do, but how we do it. The pharmaceutical industry in Australia has a mature perspective on ethics and compliance, supported by the Medicines Australia Code of Conduct. By embracing the principles of the Code, we have been able to support our partners during the pandemic, foster innovation through risk-based decision making, adapt to changing community standards.”
Rady Johnson, Executive Vice President, Chief Compliance, Quality & Risk Office at Pfizer, serves as the Chair of the Ethics and Business Integrity Committee of IFPMA. He said “IFPMA and its members are committed to helping advance ethical business practices that serve the pharmaceutical and health-related sectors around the globe. This research reinforces the value and benefit of doing business with integrity for companies of all sizes.”
Thomas Cueni, Director General of IFPMA and Industry Co-Chair of the APEC Biopharmaceutical Working Group on Ethics, agreed and added that “This study shows that companies are putting greater attention on adopting ethics programmes, adding them into a broader environmental, social and governance framework. During COVID-19, trust has been vital to innovation and delivery of health technologies across the world: from building partnerships to scale-up production of vaccines and medicines, to working with regulators for the approval of these”.
“This study sends a strong message to businesses everywhere that a robust ethics and compliance program is a competitive advantage,” said Diane Farrell, Acting Under Secretary for International Trade at the U.S. Department of Commerce. “It also illustrates the importance of global companies helping to advance the practices of third parties by clearly stating expectations and also providing guidance and resources to improve program maturity.”
The research indicated that surveyed companies were more likely to grow revenues locally and with international customers, add employees, increase employee wages, and expand businesses into new markets. The research was undertaken as part of the Business Ethics for APEC SMEs Initiative, the world’s largest public-private, multi-sectoral partnership to advance business ethics in the medical device and biopharmaceutical sectors.
The survey was distributed by Ethisphere in collaboration with diverse industry organisations representing health-related SMEs across the APEC region. The survey was conducted from 18 August to 20 September 2021 and received more than 220 responses from spanning 18 APEC economies. All respondents were SMEs in health-related industries with less than 1,000 employees.
News - MedTech & Diagnostics
Roche unlocks new horizons for genomic research in Asia Pacific
Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]
MoreNews - Pharmaceuticals
‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly
The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]
MoreNews - MedTech & Diagnostics
More public hospitals turn to same-day hip and knee surgery, but key blind spots persist
Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]
MoreNews - Pharmaceuticals
TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning
The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]
More